Potential role of upadacitinib in cytomegalovirus colitis recurrence
This case provides insights into managing cytomegalovirus (CMV)-related adverse effects in patients receiving Janus kinase (JAK) inhibitors.The risk of CMV disease, including CMV colitis, should be considered owing to lymphocyte reduction during upadacitinib treatment.
Authors
- Atsushi Ogawa (ORCID: https://orcid.org/0000-0001-5240-3395)
- Hisanori Uehara (ORCID: https://orcid.org/0000-0003-1709-1386)
- Mitsuhiro Goda (ORCID: https://orcid.org/0000-0001-5345-1479)
- Keisuke Ishizawa
- Kei Kawada (ORCID: https://orcid.org/0000-0003-1397-6128)
- Kaito Tsujinaka
- Marina Kannno
Institutions
- Hiroshima University (JP)
- Tokushima University Hospital (JP)
- Tokushima University (JP)
Publication Details
- Journal
- European Journal of Case Reports in Internal Medicine
- Published
- 2025-04-18
- DOI
- https://doi.org/10.12890/2025_005309
- Citations
- 1
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- University of Tokushima